Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies

  • Serena Meraviglia | dieli@unipa.it Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.
  • Carmela La Mendola Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.
  • Valentina Orlando Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, .
  • Francesco Scarpa Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.
  • Giuseppe Cicero Dipartimento di Discipline Chirurgiche ed Oncologiche, Universita` di Palermo, Palermo, Italy.
  • Francesco Dieli Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` di Palermo, Palermo, Italy.

Abstract

The potent anti-tumor activities of γδ T cells, their ability to produce pro-inflammatory cytokines, and their strong cytolytic activity have prompted the development of protocols in which γδ agonists or ex vivo-expanded γδ cells are administered to tumor patients. γδ T cells can be selectively activated by either synthetic phosphoantigens or by drugs that enhance their accumulation into stressed cells as aminobisphosphonates, thus offering new avenues for the development of γδ T cell-based immunotherapies. The recent development of small drugs selectively activating Vγ9Vδ2 T lymphocytes, which upregulate the endogenous phosphoantigens, has enabled the investigators to design the experimental approaches of cancer immunotherapies; several ongoing phase I and II clinical trials are focused on the role of the direct bioactivity of drugs and of adoptive cell therapies involving phosphoantigen- or aminobisphosphonate-activated Vγ9Vδ2 T lymphocytes in humans. In this review, we focus on the recent advances in the activation/expansion of γδ T cells in vitro and in vivo that may represent a promising target for the design of novel and highly innovative immunotherapy in patients with hematologic malignancies.

Downloads

Download data is not yet available.
Published
2011-12-14
Section
Reviews
Keywords:
Vc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - CytotoxicityVc9Vd2 T cells - Hematologic malignancies - Immunotherapy - Cytokines - Cytotoxicity
Statistics
Abstract views: 1047

FULL TEXT: 195
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Meraviglia, S., La Mendola, C., Orlando, V., Scarpa, F., Cicero, G., & Dieli, F. (2011). Vγ9Vδ2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies. Oncology Reviews, 4(4), 211-218. https://doi.org/10.4081/oncol.2010.211